Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Rating) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $13.45 and traded as high as $13.62. Global X Genomics & Biotechnology ETF shares last traded at $13.60, with a volume of 2,390 shares traded.
Global X Genomics & Biotechnology ETF Stock Up 1.7 %
The firm's 50-day moving average is $13.01 and its two-hundred day moving average is $13.45.
Get
Global X Genomics & Biotechnology ETF alerts:
Institutional Trading of Global X Genomics & Biotechnology ETF
Several institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its position in shares of Global X Genomics & Biotechnology ETF by 518.3% during the 3rd quarter. Royal Bank of Canada now owns 187,751 shares of the company's stock valued at $2,357,000 after acquiring an additional 157,385 shares during the last quarter. One Capital Management LLC grew its holdings in shares of Global X Genomics & Biotechnology ETF by 0.6% in the 3rd quarter. One Capital Management LLC now owns 415,101 shares of the company's stock valued at $5,209,000 after buying an additional 2,422 shares during the period. Envestnet Asset Management Inc. acquired a new position in shares of Global X Genomics & Biotechnology ETF in the 3rd quarter valued at $208,000. Nomura Asset Management Co. Ltd. boosted its stake in Global X Genomics & Biotechnology ETF by 49,700.0% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 49,800 shares of the company's stock worth $625,000 after purchasing an additional 49,700 shares during the period. Finally, Simplex Trading LLC boosted its stake in Global X Genomics & Biotechnology ETF by 198.6% in the 3rd quarter. Simplex Trading LLC now owns 2,311 shares of the company's stock worth $29,000 after purchasing an additional 1,537 shares during the period.
Global X Genomics & Biotechnology ETF Company Profile
(Get Rating)
Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.
Featured Articles
- Get a free copy of the StockNews.com research report on Global X Genomics & Biotechnology ETF (GNOM)
- Why Warner Bros Discovery Is the S&P's Hottest Stock
- Pinterest is the Social Commerce Platform to Watch in 2023
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- 4 High-Yield Dividend Kings For 2023
- Will 2023 be a Good Year for Goodyear Tire Stock?
Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
在週一的交易中,全球X基因生物技術ETF(納斯達克代碼:GNOM-GET評級)的股價突破了200日移動均線。該股的200日移動均線切入位為13.45美元,最高交易價格為13.62美元。Global X Genology&Biotech ETF股票最新報13.60美元,總成交量為2390股。
Global X基因組和生物技術ETF股票上漲1.7%
該公司的50日移動均線切入位在13.01美元,200日移動均線切入位在13.45美元。
到達
全球X基因組和生物技術ETF警報:
全球X基因組和生物技術ETF的機構交易
幾家機構投資者和對沖基金最近改變了他們在該業務中的頭寸。加拿大皇家銀行在第三季度將其在環球X基因生物技術ETF的股票持倉量提高了518.3%。加拿大皇家銀行在上個季度增持了157,385股後,現在持有187,751股公司股票,價值2,357,000美元。One Capital Management LLC在第三季度增持了Global X基因組學和生物技術ETF的股票0.6%。One Capital Management LLC現在擁有該公司415,101股股票,價值5,209,000美元,在此期間又購買了2,422股。Envestnet Asset Management Inc.在第三季度收購了Global X基因組和生物技術ETF的新頭寸,價值20.8萬美元。野村資產管理有限公司(Nomura Asset Management Co.)在第三季度將其在Global X基因組和生物技術ETF的持股增加了49,700.0%。野村資產管理有限公司(Nomura Asset Management Co.Ltd.)在此期間購買了49,700股野村資產管理公司的股票,目前持有49,800股該公司股票,價值625,000美元。最後,Simplex Trading LLC在第三季度將其在Global X基因組和生物技術ETF中的持股增加了198.6%。Simplex Trading LLC現在擁有2311股該公司股票,價值2.9萬美元,在此期間又購買了1537股。
全球X基因組和生物技術ETF公司簡介
(獲取評級)
完整基因組公司是一家生命科學公司,已經開發了脫氧核糖核酸(DNA)測序平臺並將其商業化。其完整的基因組分析平臺(CGA)將其人類基因組測序技術與先進的資訊學和數據管理軟體以及端到端外包服務模式相結合,為其客戶提供可用於基於基因組的研究的數據。
專題文章
- 免費獲取StockNews.com關於Global X基因組和生物技術ETF(GNOM)的研究報告
- 為什麼華納兄弟探索成為標準普爾最熱門的股票
- Pinterest是2023年值得關注的社交商務平臺
- 沃爾格林靴子聯盟的收益低於預期對投資者有利嗎?
- 2023年4大高收益股利之王
- 2023年對固特異輪胎庫存來說會是一個好年份嗎?
獲得全球X基因組和生物技術ETF日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收關於Global X基因組學和生物技術ETF及相關公司的最新新聞和分析師評級的每日簡明摘要。